Risk factors and outcomes for bloodstream infections with extended-spectrum beta -lactamase-producing Klebsiella pneumoniae ; Findings of the nosocomial surveillance system in Hungary.

Risk factors for and outcomes of bloodstream infections (BSIs) caused by ESBL-producing and by ESBL-non-producing Klebsiella pneumoniae were compared in a four-year multicenter study in Hungary. One hundred ESBL-positive and one hundred ESBL-negative patients were included as cases and controls. Investigated risk factors were related to demographics, comorbid conditions, treatments, invasive procedures, surgery prior bacteremia, presence of additional nosocomial infections and preceding hospital admission within a year. Measured outcomes were crude mortality, mortality related to infection and delay in introducing appropriate therapy (DAT). Though some risk factors for infection (admission to intensive care units, having central venous and/or urinary catheter, mechanical ventilation) were shared by both groups, in other respects cases and controls were found to differ substantially. The 36 percent of patients with BSIs with ESBL-producing Klebsiella died versus 23 percent of controls (odds ratio [OR]: 2.5; 95% confidence interval [CI]: 1.0-5.4; p = 0.02). The 18 percent of deaths in cases versus 9% in controls could be attributed to infection (OR: 5.0; 95% CI: 1.5-16.2; p = 0.006). Cases more often received previous antibiotic therapy than controls (OR: 2.7; 95% CI: 1.1-6.7; p = 0.02) and delay in the introduction of appropriate antibiotic treatment was observed in 44% of cases versus 19% of controls (OR: 3.4; 95% CI: 1.6-7.3; p = 0.001). The results demonstrate that BSIs caused by ESBL-producing K. pneumoniae are related to previous antibiotic therapy and are associated with a high rate of mortality that is often linked to delay in the introduction of appropriate antibiotic therapy. This confirms that besides infection control measures the early identification and antibiotic resistance profiling of the infecting pathogen is salient in the control of BSIs caused by ESBL-producing K. pneumoniae .

[1]  M. Shanthi,et al.  Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2010, The Journal of the Association of Physicians of India.

[2]  E. Horváth-Puhó,et al.  The national nosocomial surveillance network in Hungary: results of two years of surgical site infection surveillance. , 2009, The Journal of hospital infection.

[3]  F. Baquero,et al.  Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  A. Montano‐Loza,et al.  Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[5]  I. Damjanova,et al.  Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'? , 2008, The Journal of antimicrobial chemotherapy.

[6]  R. Cordery,et al.  Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome , 2008 .

[7]  D. Paterson,et al.  Extended-spectrum beta-lactamase-producing Klebsiella spp. in a neonatal intensive care unit: risk factors for the infection and the dynamics of the molecular epidemiology , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  G. Fadda,et al.  Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment , 2007, Antimicrobial Agents and Chemotherapy.

[9]  M. Kaufmann,et al.  Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. , 2006, The Journal of hospital infection.

[10]  R. Ramphal,et al.  Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data , 2006 .

[11]  Yehuda Carmeli,et al.  Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae , 2006, Antimicrobial Agents and Chemotherapy.

[12]  Ronald N. Jones,et al.  Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. , 2006, Diagnostic microbiology and infectious disease.

[13]  R. Ramphal,et al.  Extended-spectrum beta-lactamases and clinical outcomes: current data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Mehio-Sibai,et al.  Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. , 2005, American journal of infection control.

[15]  W. Bilker,et al.  Risk Factors for and Outcomes of Bloodstream Infection Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species in Children , 2005, Pediatrics.

[16]  G. Jacoby,et al.  The new beta-lactamases. , 2005, The New England journal of medicine.

[17]  G. Jacoby,et al.  Mechanisms of disease: The new β-lactamases , 2005 .

[18]  S. Mitsuhashi,et al.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens , 1983, Infection.

[19]  S. Cosgrove,et al.  The impact of antimicrobial resistance on health and economic outcomes. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M.-L. Huang,et al.  Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. , 2003, The Journal of hospital infection.

[21]  E. Kim,et al.  Bloodstream Infections by Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Children: Epidemiology and Clinical Outcome , 2002, Antimicrobial Agents and Chemotherapy.

[22]  W. Bilker,et al.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  P. West.  Extended-spectrum beta-lactamase-producing Klebsiella spp. , 2000, British journal of biomedical science.

[24]  P. Lagrange,et al.  [Extended spectrum beta-lactamases]. , 1989, La Revue du praticien.

[25]  G. Jacoby,et al.  Extended-spectrum beta-lactamases , 1989, Antimicrobial Agents and Chemotherapy.